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Plasmodium falciparumTerpenoid precursor biosynthesis occurs in human and many pathogenic organisms via the meva-
lonate and 2-C-methyl-D-erythritol-4-phosphate (MEP) pathways, respectively. We determined the
X-ray structure of the Fe/S containing (E)-4-hydroxy-3-methyl-but-2-enyl-diphosphate reductase
(LytB) of the pathogenic protozoa Plasmodium falciparum which catalyzes the terminal step of the
MEP pathway. The cloverleaf fold and the active site of P. falciparum LytB corresponds to those of
the Aquifex aeolicus and Escherichia coli enzymes. Its distinct electron donor [2Fe–2S] ferredoxin
was modeled to its binding site by docking calculations. The presented structural data provide a
platform for a rational search of anti-malarian drugs.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Malaria is considered as one of the world’s leading causes of
morbidity and mortality with annually over 500 million symptom-
atic infections and 1 million lethal cases [1]. Infections to humans
are caused by parasitic protozoa of the genus Plasmodium that is
subdivided into the four pathogenic species Plasmodium falciparum,
Plasmodium vivax, Plasmodium ovale and Plasmodium malariae. P.
falciparum, the causative agent of malignant tertian malaria
(malaria tropica), is the most dangerous among them and respon-
sible for the majority of the lethal cases [1]. As P. falciparum
increasingly developes resistances against commonly used drugs
for therapeutic and prophylactic purposes [2] identiﬁcation of no-
vel targets for ﬁnding anti-malarial agents is of prime importance.
Terpenoids such as dolichols, quinones, carotenoids, vitamins
and sterols, are involved in vital metabolic processes in allkingdoms of life. Despite their great diversity with over 35000 dis-
tinct compounds, all terpenoids are derived from the two 5-carbon
isoprene precursors isopentenyl diphosphate (IPP) and dimethylal-
lyl diphosphate (DMAPP). Interestingly, nature has evolved two
distinct pathways for their biosynthesis: the mevalonate and the
2-C-methyl-D-erythritol-4-phosphate (MEP) pathways. Animals,
fungi, archaea and some bacteria use the well-known mevalonate
pathway, the vast majority of bacteria and some parasitic protozoa
of the phylum Apicomplexa, the MEP pathway [3–5]. Since the
MEP pathway is not used by humans, it is considered as an attrac-
tive target for the development of new antimicrobial agents, in
particular, drugs against the parasitic protozoa Plasmodium,
responsible for the malaria disease [6–9]. Enzymes of the MEP
pathways have been thoroughly explored in the last 20 years with
respect to their molecular and functional properties [10]. The
terminal enzyme of the MEP pathway, (E)-4-hydroxy-3-methyl-
but-2-enyl-diphosphate reductase (LytB/IspH) converts (E)-4-hy-
droxy-3-methyl-but-2-enyl-diphosphate (HMBPP) into IPP and
DMAPP (Fig. 1) [11]. LytB was characterized as [4Fe–4S] carrying
monomeric or dimeric enzyme with of a molecular mass of
30–35 kDa per monomer. X-ray structures were recently deter-
mined for the Aquifex aeolicus and Escherichia coli enzymes; the
latter in complex with substrate and products. On this basis a
structure-based mechanism could be postulated and inhibition
studies initiated [12–15].
Fig. 1. Reaction of LytB which converts HMBPP into IPP or DMAPP. Electrons to the
[4Fe–4S] cluster of LytB are supplied in P. falciparum by the ferredoxin/ferredoxin-
NADP+ reductase system. NADPH transfers a hydride to FAD that conducts two
times one electron to a [2Fe–2S] cluster of ferredoxin and further to the [4Fe–4S]
cluster of LytB.
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strate and electron donor binding sites of LytB of P. falciparum, the
direct target for drug developments against the major pathogenic
malaria parasite.
2. Materials and methods
2.1. Enzyme production
TOP 10 E. coli cells (Invitrogen) were transformed with the
pASKPfalLytB vector containing His6-tagged LytB and grown in
LB-broth medium (Roth) supplemented with 150 lg ml1 ampicil-
lin and 300 lM FeCl3 at 37 C [16]. The cells were harvested by
centrifugation (17700g, 15 min, 4 C) and stored at 30 C until
further use. All subsequent steps were carried out under oxygen
exclusion. The cell pellet (30 g) was resuspended in 300 ml
30 mM Tris–HCl (pH 7.5), 150 mM NaCl, 15 mM imidazole and
lysed by ultrasonic treatment at 0 C. Puriﬁcation was performed
using Co-TALON, Source 15S and Superdex 200 columns as de-
scribed in detail in the Supplementary data. LytB was stored at a
concentration of ca. 12 mg ml1 in 30 mM Tris–HCl (pH 7.5) and
150 mM NaCl.
2.2. Crystallization and X-ray structure analysis
Crystallization was performed at 18 C in an anaerobic tent (95%
N2, 5% H2) using the sitting drop vapour diffusion method. Best
crystals grew by mixing 2.0 ll enzyme solution (12 mg ml1 LytB,
30 mM Tris–HCl, 150 mM NaCl, pH 7.5) and 1.0 ll reservoir solu-
tion composed of 30% w/v PEG 4000, 100 mM sodium citrate (pH
5.6) and 100 mM ammonium sulfate. Data were collected at the
Swiss-Light source beamline PXII and processed with XDS [17].
The structure was determined with the multiple anomalous dis-
persion method using the iron of the Fe/S cluster as anomalous
scatterer. The iron positions were detected with SHELXD [18] and
the phases calculated with SHARP [19]. After phase improvement
with SOLOMON [20] a polypeptide model could be built in COOT
[21] using the known LytB structures [12,13]. The structure was re-
ﬁned with REFMAC5 [22]. Crystal parameters, data collection and
reﬁnement statistics are listed in Table 1. Figs. 1–3 were produced
with PYMOL (Schrödinger, LLC]. The atomic coordinates and the
structure factor of LytB have been deposited in the Protein Data
Bank, www.pdb.org with the ID code 4N7B.2.3. Docking calculations
Fully unbiased protein–protein docking calculations on the ba-
sis of the determined LytB structure and the known ferredoxin
structure from P. falciparum (PDB: 1iue) were performed with the
molecular simulations software ICM-Pro (Molsoft LLC, La Jolla,
CA) [23]. We calculated the size of the surface area buried at the
interface, the number of hydrophobic contacts, binding energies,
and overall electrostatic complementarities and reduced the gen-
erated number of LytB–ferredoxin complexes by deﬁning a maxi-
mal distance between the redox centers involved in inter-protein
electron transfer. A number of scripts were written to calculate
interatomic distances, angles and torsion angles, as well as to eval-
uate the binding energies of the generated complexes. The most
promising docking complexes were chosen and further reﬁned by
energy minimization and side chain optimization procedures. The
software ICM-ODA (optimal docking area) [24] was used to deter-
mine the surface section of LytB that is most suitable to form an
interface with another protein.3. Results and discussion
3.1. Structure of LytB of P. falciparum
Recombinantly produced His6-tagged LytB enzyme from P. falci-
parumwascrystallizedunderanaerobic conditions. Its structurewas
determined by the multiple anomalous dispersion method and re-
ﬁned toﬁnalR/Rfree factorsof 17.5/19.5%at2.2 Å resolution (Table1).
In accordance to previous solution data [16] P. falciparum LytB
was found like E. coli LytB as a monomer in contrast to the dimeric
A. aeolicus LytB. P. falciparum LytB is essentially composed of three
related a/b-domains (domains A–C) arranged in a cloverleaf form
with the Fe/S-cluster in its center (Fig. 2; Supplementary Fig. 1A).
This architecture corresponds to that of A. aeolicus and E. coli LytB
[12,13]. In contrast to the A. aeolicus enzyme, the P. falciparum and
E. coli enzymes contain a C-terminal extension fused to helix a4c.
After a turn it linearly spans over the entire domain C and is partly
associated as a strand to the central four-stranded parallel b-sheet.
Subsequently, the C-terminal extension passes the backside of the
Fe/S cluster and continues to the top of domain A. In contrast to
E. coli LytB the terminal residues of the P. plasmodium enzyme
are folded as an a-helix (a1D) which is attached to helix a1A
(Fig. 2A). Superposition between the different LytB structures with
DALI [25] results in an rms deviation of 3.0 Å between P. falciparum
and A. aeolicus LytB (sequence identity 32%) and of 1.4 Å between P.
falciparum and E. coli LytB (sequence identity 40%).
This higher similarity between the latter enzymes is mainly due
to a large-scale conformational change of the variable domain C
(Fig. 2B). A. aeolicus LytB is crystallized in an open state [12]
whereas P. falciparum and E. coli LytB in a closed state [13].
Open-to-close transition implicates a rotation of domain C towards
the active site crevice. Interestingly, domain C of E. coli LytB is ro-
tated ca. 10 further down to the active site crevice than domain C
of P. falciparum LytB resulting in displacements at its top up to 5 Å.
Further signiﬁcant deviations up to 5 Å between the known LytB
structures are only found in the loops following helices a2B, a3B
and a4C. The loop following helix a1A is conformationally distinct
between A. aeolicus and P. falciparum/E. coli LytB. These differences
do, however, not affect the active site structure.
3.2. The Fe/S-cluster and the catalytic site
The P. falciparum LytB crystal structure exhibits an inactive
[3Fe–4S] cluster already observed in A. aeolicus and most E. coli
LytB structures [12,13]. The three iron atoms are ligated to three
Table 1
Data collection and reﬁnement statistics.
Data set Native Peak Inﬂection Remote
Data collection
Wavelength (Å) 0.92 1.7382 1.7406 1.7141
Space group P3121 P3121 P3121 P3121
Resolution (Å) 2.2–50.0 (2.2–2.3) 2.4–50.0 (2.4–2.5) 2.6–50.0 (2.6–2.7) 2.6–50.0 (2.6–2.7)
Cell axis (Å) 116.1, 77.0 115.8, 76.8 115.9, 76.6 115.6, 76,8
Completeness (%) 99.5 (99.8) 99.6 (99.2) 99.6 (99.3) 99.7 (99.3)
Rsym (%) 8.9 (79.5) 7.4 (69.3) 6.9 (45.4) 8.4 (38.2)
I/sigI 15.5 (5.5) 14.1 (3.0) 17.3 (4.4) 14.5 (5.0)
Redundancy 6.0 (6.0) 5.5 (5.0) 4.9 (4.8) 4.9 (4.9)
Reﬁnement statistics
No. of mon. in a.u. 1
No. of residues, [4Fe–4S] clusters, solvents in a.u. 318, 1, 189
Resolution (Å) 2.2–50.0 (2.26–2.20)
Rworking, Rfree (%) 17.5, 19.5 (26.0, 27.9)
Baverage (polypeptide, [4Fe–4S] cluster, solvent) (Å2) 45.6, 26.4, 44.6
R.m.s. deviation bond lengths (Å) 0.009
Bond angles () 1.45
Fig. 2. Structure of P. falciparum LytB. (A) Monomeric LytB is composed of three a/b-domains (domain A: yellow; domain B: green; domain C: blue) and a C-terminal
extension (red). The central [3Fe–4S]-cluster is ﬁxed by cysteines from all three domains. (B) Alignment of the domains A and B core of P. falciparum (red), E. coli (blue) and A.
aeolicus LytB (green). Domain C of P. falciparum and E. coli LytB is rotated towards the frontside of the active site forming a closed conformation; domain C of A. aeolicus LytB is
in an open conformation.
Fig. 3. Active site of P. falciparum LytB (stick model) and E. coli LytB–HMPBB
complex (line model). The Fe/S cluster and crucial residues for substrate binding
and catalysis are superimposed showing their high similarity.
3970 I. Rekittke et al. / FEBS Letters 587 (2013) 3968–3972strictly conserved cysteines (Cys14, Cys98 and Cys196) that pro-
trude from each of the domains and thus link them together. The
complete [4Fe–4S] cluster contains a non-cysteine bound iron that
points towards bulk solvent [14] and becomes readily dissociated
during the crystallization process. The substrate binding site is lo-
cated in front of the iron-sulfur cluster inside a crevice that is
formed by loops following strands b1 (b1A, b1B, b1C), b3 and 4
(Fig. 2A, Supplementary Fig. 1A). The accurate binding of the
substrate HMBPP and its conformation is known from the
LytB–HMBPP complex of E. coli [14].
The active site appears to be formed by an open-to-close transi-
tion process triggered by substrate binding. Domain C is rotated to-
wards the front of the molecule and thus encapsulates the Fe/S
cluster and the active site against bulk solvent (Fig. 2B). The closed
conformation of P. falciparum LytB is presumably induced by a sul-
fate molecule positioned at the b-phosphate binding site of HMBPP
found in the E. coli LytB–HMBPP complex (Fig. 3) [14]. (The preci-
pitant solution contains 100 mM ammonium sulfate). The different
position of domain C relative to the core (domain A+B) (Fig. 2B) in
E. coli and P. falciparum LytB might be due to structural differences
between diphosphate (or HMBPP) and sulfate, respectively, to
sequence differences between the two LytB or to crystal lattice ef-
fects that, in particular, inﬂuence the ﬂexible domain C.
Fig. 4. Plausible complexes between LytB and ferredoxin from P. falciparum generated by protein–protein docking calculations (ICM-Pro, Molsoft). (A) The six energetically
most favorable LytB–ferredoxin complexes are presented with LytB in a molecular surface and ferredoxin in a Ribbon representation. Negative electrostatic surface potentials
for LytB are shown in red, positive ones in blue. (B) The interface between LytB and ferredoxin. The ferredoxin is colored in wheat, domains A–C of LytB in yellow, green and
blue, the C-terminal extension in red, and Fe and S of the Fe/S cluster as orange and yellow spheres. (C) Detailed interactions between LytB and ferredoxin. Side chains are
shown as sticks. The formation of only few speciﬁc polar interactions between LytB and ferredoxin, according to the docking calculations performed, is compatible with the
physiological requirement for a rather weak protein–electron donor complex.
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served residues His43, His76, His126, Glu128 and Thr97 involved
in substrate binding are found in a virtually identical conformation
and position in P. falciparum and E. coli LytB documented by an rms
deviation of <0.5 Å. (Fig. 3). While the surrounding of the methylb-
utenyl binding site of HMBPP including Thr97 and Glu128 is nearly
identical, that of the diphosphate indicates a few minor differences
in the second interaction shell. For example, Ser226 of a serine
cluster (Ser226, Ser228 and Ser268) in E. coli LytB interacts with
the b-phosphate of HMBPP and is hydrogen-bonded to the
Asn229 side chain [14]. The equivalent Lys228 of P. falciparum LytB
is directed to bulk solvent. Moreover, Ser228 of E. coli LytB involved
in a-phosphate binding of HMBPP is replaced by an alanine in P.
falciparum LytB. Differences are also found in the loop following
strand b1A that is stabilized in P. falciparum LytB by a pronounced
salt bridge between Lys40 and Asp45. Notably, His39 is turned to-
wards His43 in the P. falciparum LytB and in the E. coli Lytb-PPi
structures but not in the E. coli LytB–HMBPP structure [14]. The
found high degree of structural conservation among the LytB
family members (Fig. 3, Supplementary Fig. 1B) clearly argue for
a virtually identical substrate binding mode and catalytic mecha-
nism best studied for the E. coli enzyme [14]. Therefore the com-
bined information of the P. falciparum and E. coli LytB structures
provide a serious platform for designing knowledge-based
substrate inhibitors on a rational basis.3.3. Putative binding of the electron donor [2Fe–2S] ferredoxin
Biochemical studies revealed that P. falciparum uses the ferre-
doxin/ferredoxin-NADP+ reductase system for donating electrons
to the [4Fe–4S] cluster of LytB (Fig. 1). They further demonstrated
that LytB and a [2Fe–2S] ferredoxin form in vitro at low salt con-
centrations a relatively stable complex [16]. Since most organisms
including E. coli and presumably A. aeolicus use the ﬂavodoxin/ﬂa-
vodoxin-NADP+ reductase system [26] as electron donor for LytB,
the LytB–ferredoxin interface offers a very speciﬁc target for devel-
oping inhibitors for P. falciparum LytB. The contact region and the
speciﬁc interactions between LytB and ferredoxin are, however,
not structurally established which prompted us to perform in silico
docking studies.
Qualitative protein surface analysis of LytB suggested the bind-
ing site for ferredoxin on its backside because only then a realistic
distance for an effective electron transfer (13–14 Å) between the
[4Fe–4S] and the [2Fe–2S] clusters can be adjusted without inter-
fering with the catalytic site (Fig. 4). Ferredoxin might attach to a
shallow well formed by the C-terminal extension, helix a1B and
the loops after strands b4A and b4B. These assumption was con-
ﬁrmed by unbiased docking calculations using the ICM-Pro soft-
ware [23]. Ca. 21000 hits were generated; 31 of them remained
when permitting only distances between [4Fe–4S] cluster of LytB
and [2Fe–2S] cluster of ferredoxin of 613 Å and energy scores
3972 I. Rekittke et al. / FEBS Letters 587 (2013) 3968–3972620 kcal/mol. The six LytB–ferredoxin complexes with the low-
est energy are examined in detail (Fig. 4A, Supplementary Table 1).
In the best solutions the LytB–ferredoxin interfaces are very sim-
ilar and only distinguished by the rotation angle between LytB and
ferredoxin around an axis that links the two iron–sulfur clusters of
both proteins. In complexes 3 and7 LytB and ferredoxin adopt a sim-
ilar orientation, whereas, in comparison, in complex 36 they are ro-
tated by180 around thementioned axis. Complexes 10, 12 and38
moderately deviate from complex 3 (Fig. 4A). Optimal Docking Area
(ODA) calculations [24], that determine the most likely docking site
to another proteinwithout applying distance restraints result in the
same solution as the docking simulations (Supplementary Fig. 2).
However, a clear top candidate (if one exists) under the best docking
solutionswasnotdetectablewhichmightbepossiblewithextensive
molecular dynamics simulations to optimize the intermolecular
contacts and, of course, by a crystal structure of the LytB–ferredoxin
complex. Themost probable candidate according to the current data
is the LytB–ferredoxin complex3 (Fig. 4). It forms themaximal num-
ber of speciﬁc hydrogen bonds and exhibits the lowest energy score
value (36.5 kcal/mol) which is the third best value of all ca. 21000
LytB-ferredoxin complexes calculated without distance restraints.
In the best solutions the protein–protein contact is essentially
accomplished by the same residues including Leu100, Lys103,
Tyr107, Ser192, Tyr197, Asn201, Lys302, Trp303, Lys304, Lys307
of LytB and Arg40, Thr46, Ser62, Tyr63, Asp60, Asp65, Tyr80,
Glu92 of ferredoxin (Fig. 4B+C). It becomes obvious that the
C-terminal extension – if present – plays a crucial role in ferre-
doxin binding. Segment 37–46 of ferredoxin that envelops and
thereby shields the [2Fe–2S] cluster is embedded into the shallow
well. Residues Ser38, Ser43, Thr46, Ser 62, and Tyr63 of ferredoxin
form an extended hydrophobic contact with Pro99, Leu100,
Lys103, Tyr107, Ser192, Pro301 and Trp303 of LytB. A key role in
electron transfer is attributed to Trp303 which is located in all
docked LytB–ferredoxin complexes between the iron–sulfur clus-
ters and is frequently in van der Waals contact to them. Trp303
sandwiched between Pro99 and Pro301, is projected towards bulk
solvent in LytB and shielded after ferredoxin binding (Fig. 4C). It is
also directly neighbored to Tyr197, the residue calculated in ODA
to be most likely involved in the LytB–protein interface. A compar-
ison between the C-terminal extensions of P. falciparum and E. coli
LytB in the electron donor binding region revealed an rms devia-
tion of 2.5 Å for the backbone atoms and only a moderate conser-
vation of the side chains. Val300, Pro301, Lys302, Trp303 and
Lys304 are exchanged to asparagine, isoleucine, valine, phenylala-
nine and glutamate. Substantial differences between the two en-
zymes are also found in other segments forming the assumed
ferredoxin binding site (Supplementary Fig. 3). One example is
the loop following strand b4B (Fig. 4C) which is displaced ca. 5 Å
in P. falciparum compared to E. coli LytB.
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